NIH VideoCast - NEI AGI Seminar: Human iPSC-derived 3D retinal tissue for stem cell-based therapies for retinal degenerative diseases

Skip Navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

NEI AGI Seminar: Human iPSC-derived 3D retinal tissue for stem cell-based therapies for retinal degenerative diseases

Loading... Loading video...

363 Views

Air date:	Friday, November 19, 2021, 1:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 363 (192 Live, 171 On-demand)
Category:	Special
Runtime:	01:02:49
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Dr. Canto-Soler completed her Ph.D. in Biomedical Sciences at Austral University in Argentina and a postdoctoral fellowship at the Wilmer Eye Institute, Johns Hopkins University. She joined the Wilmer faculty as a research associate in 2006 and was promoted to assistant professor in 2008. In July 2017 she joined the Department of Ophthalmology at the University of Colorado School of Medicine as the Doni Solich Family Chair in Ocular Stem Cell Research and the Director of CellSight – the Ocular Stem Cell and Regeneration Research Program. Over the years she has received several national and international awards including the POEN Award for Best Research Study in Ophthalmology, the Alcon Research Institute Young Investigator Award, and the William & Mary Greve Special Scholar Award from Research to Prevent Blindness. She has also been named Outstanding Personality by the Council of the Autonomous City of Buenos Aires, Argentina, in recognition to her scientific contributions. Using human induced pluripotent stem cells (hiPSC), Dr. Canto-Soler and her research team established a method that led for the first time to the generation of light-sensitive miniature human retinas in a laboratory dish. At CellSight, Dr. Canto-Soler and colleagues are currently using this breakthrough technology to develop novel stem cell-based therapeutics to save and restore sight in patients with blinding diseases. As a leading researcher in vision, Dr. Canto-Soler has a recent publication that provides the first evidence that proteins known to form drusen, which are yellowish deposits that accumulate under the retina and that contribute to age-related macular degeneration (AMD), are released and directionally sorted in extracellular vesicles from retinal pigment epithelium (RPE) cells. This research, just published in the Journal of Extracellular Vesicles, offers some of the first insight into mechanisms underlying early manifestations of AMD and could lead to early diagnoses and targeted treatment options of dry AMD: https://onlinelibrary.wiley.com/doi/10.1002/jev2.12165. For more information go to https://www.nei.nih.gov/about/goals-and-accomplishments/nei-research-initiatives/audacious-goals-initiative/events-and-reports/agi-seminar-human-ipsc-derived-3d-retinal-tissue

NLM Title:	Human iPSC-derived 3D retinal tissue for stem cell-based therapies for retinal degenerative diseases / Maria Valeria Canto-Soler.
Author:	Canto-Soler, Maria Valeria. National Eye Institute,
Publisher:
Abstract:	(CIT): Dr. Canto-Soler completed her Ph.D. in Biomedical Sciences at Austral University in Argentina and a postdoctoral fellowship at the Wilmer Eye Institute, Johns Hopkins University. She joined the Wilmer faculty as a research associate in 2006 and was promoted to assistant professor in 2008. In July 2017 she joined the Department of Ophthalmology at the University of Colorado School of Medicine as the Doni Solich Family Chair in Ocular Stem Cell Research and the Director of CellSight - the Ocular Stem Cell and Regeneration Research Program. Over the years she has received several national and international awards including the POEN Award for Best Research Study in Ophthalmology, the Alcon Research Institute Young Investigator Award, and the William & Mary Greve Special Scholar Award from Research to Prevent Blindness. She has also been named Outstanding Personality by the Council of the Autonomous City of Buenos Aires, Argentina, in recognition to her scientific contributions. Using human induced pluripotent stem cells (hiPSC), Dr. Canto-Soler and her research team established a method that led for the first time to the generation of light-sensitive miniature human retinas in a laboratory dish. At CellSight, Dr. Canto-Soler and colleagues are currently using this breakthrough technology to develop novel stem cell-based therapeutics to save and restore sight in patients with blinding diseases. As a leading researcher in vision, Dr. Canto-Soler has a recent publication that provides the first evidence that proteins known to form drusen, which are yellowish deposits that accumulate under the retina and that contribute to age-related macular degeneration (AMD), are released and directionally sorted in extracellular vesicles from retinal pigment epithelium (RPE) cells. This research, just published in the Journal of Extracellular Vesicles, offers some of the first insight into mechanisms underlying early manifestations of AMD and could lead to early diagnoses and targeted treatment options of dry AMD: https://onlinelibrary.wiley.com/doi/10.1002/jev2.12165. For more information go to https://www.nei.nih.gov/about/goals-and-accomplishments/nei-research-initiatives/audacious-goals-initiative/events-and-reports/agi-seminar-human-ipsc-derived-3d-retinal-tissue.
Subjects:	Induced Pluripotent Stem Cells Retinal Cone Photoreceptor Cells Retinal Degeneration--therapy Stem Cell Transplantation
Publication Types:	Lecture Webcast

NLM Classification:	WW 270
NLM ID:	9918332581506676
CIT Live ID:	43978
Permanent link:	https://videocast.nih.gov/watch=43978

Related Videos...